Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Gliosarcoma × encorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Melanoma 9 Neoplasm Metastasis 3 Neoplasms 2 Lung Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Solid Tumors Harboring a BRAF V600 Mutation 1 Skin Neoplasms 1 Skin Diseases 1 Pancreatic Neoplasms 1 Lymphatic Metastasis 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Astrocytoma 1

Interventions

Temozolomide 48 Bevacizumab 31 Radiotherapy 24 Radiation 11 Erlotinib Hydrochloride 11 Radiotherapy, Intensity-Modulated 7 Radiotherapy, Conformal 7 Irinotecan 6 Vorinostat 5 Immunoglobulin G 4 Disulfides 4 Carmustine 4 plerixafor 3 carmustine, poliferprosan 20 drug combination 3 Sorafenib 3 Sirolimus 3 Radiosurgery 3 Magnetic Resonance Spectroscopy 3 Everolimus 3 Dasatinib 3 Bortezomib 3 veliparib 2 vandetanib 2 temsirolimus 2 tandutinib 2 sargramostim 2 pazopanib 2 ferric pyrophosphate 2 cediranib 2 Topotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡